Side-by-side financials for ERNA and MRK. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ERNA | MRK |
|---|---|---|
| Market cap | - | $294.13 B |
| US-listed rank | - | #44 |
| Revenue (latest FY) | $582.00K | $65.01B |
| Net income (latest FY) | -$14.08M | $18.25B |
| Net margin | -2419.9% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 1,000 | 996 |
In their latest fiscal years, Eterna Therapeutics Inc. reported $582.00K in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Eterna Therapeutics Inc. and Merck & Co., Inc., or browse the full rankings.